Leucine-rich repeat kinase enzyme activity

US9233977B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• John A. McCauley · Maple Glen, US
• Hemaka A. Rajapakse · Wyncote, US
• Thomas J. Greshock · Collegeville, US
• John M. Sanders · Hatfield, US
• Boyoung Kim · Lexington, US
• Vanessa L. Rada · Hatfield, US
• Jonathan T. Kern · Johnstown, US
• Heather H. Stevenson · Ardmore, US
• Mark T. Bilodeau · Waltham, US

Key dates

• Filing date: Oct 25, 2011
• Grant date: Jan 12, 2016
• Expiry date: Aug 24, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/10
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO2—, —O— or NRac—, wherein Rac is H, or C1-20 alkyl and R1 through R5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.